Results 201 to 210 of about 131,242 (269)

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti, Matt Capehorn, Esther Artime, Lill‐Brith von Arx, Alun L. Davies, Atif Adam, Anastasia Lampropoulou   +6 more
wiley   +1 more source

Effects of a Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin on Pancreas in Obese Diabetic Mice. [PDF]

In Vivo
Sekikawa R, Uehara H, Uno K, Sasase T, Nakata Y, Mori Y, Shinohara M, Sugimoto M, Ohta T.   +8 more
europepmc   +1 more source

Contents and secretion of glucagon and insulin in rat pancreatic islets from the viewpoint of their localization in pancreas.

, 1989
YOSHIMASA TASAKA, Hiroshi Matsumoto, Yukiko Inoue, Yukimasa Hirata   +3 more
openalex   +2 more sources

Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2. [PDF]

Front Mol Biosci
Shao Q, Xiong J, Wu J, Mao J, Hu Q.
europepmc   +1 more source

Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice

Fang‐Xin Jin, Yan Wang, Min‐Ne Li, Ru-jiang Li, Juntang Guo   +4 more
openalex   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, EarlyView.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Zaffar H, Imran MA, Hussain S, Rushd F.
europepmc   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Gαs defines the fundamental coupling mechanism of insulin secretion. [PDF]

J Diabetes Investig
Shirakawa J.
europepmc   +1 more source